MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Anthropic IPO Marketing Expected to Start in Mid-October 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Add as a preferred source on Google
-- Conference Call to Follow at 4:30 p.m. EDT --
HORSHAM, Pa., Feb. 21, 2018 -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, will release fourth quarter and fiscal 2017 financial results on Thursday, March 8, after the market close. STRATA Skin Sciences’ President and Chief Executive Officer, Frank J. McCaney, will host a conference call at 4:30 pm Eastern Time to review the Company’s progress and answer questions.
| Conference Call Details: | ||
| Date: | Thursday, March 8 | |
| Time: | 4:30 pm Eastern Time | |
| Toll Free: | 888-394-8218 | |
| International: | 323-794-2149 | |
| Passcode: | 6380302 | |
| Webcast: | www.strataskinsciences.com |
About STRATA Skin Sciences, Inc. (www.strataskinsciences.com)
STRATA Skin Sciences is a medical technology company focused on the therapeutic and aesthetic dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation; and NORDLYS, a multi-technology aesthetic laser device.
| Investor Contacts: | ||
| Frank McCaney, Chief Executive Officer | Bob Yedid, Managing Director | |
| STRATA Skin Sciences, Inc. | LifeSci Advisors, LLC | |
| 215-619-3200 | 646-597-6989 | |
| [email protected] | [email protected] |
